Revenue from Collaboration and License Agreements (Tables)

3 Months Ended

Mar. 31, 2020

Summary of Net Revenue from Partners in Connection with Collaboration and License Agreements

Net revenue from our partners in connection with our collaboration and license agreements consisted of the following (in thousands):

	Three Months Ended March 31,
	2020		2019
Strategic Collaboration with Novartis	$	311	$	157,062
Vupanorsen (AKCEA-ANGPTL3-LRx)License Agreement with Pfizer		604		—
Total net revenue from partners	$	915	$	157,062

Summary of Balance of Receivables and Contract Liabilities Related to Net Product Revenue

The following table presents the balance of our receivables and contract liabilities related to net product revenue (in thousands):

	March 31, 2020		December 31, 2019
Receivables included in "Accounts receivable"	$	10,330	$	6,946
Contract liabilities included in "Accrued liabilities"		2,645		1,550

Summary of Revenue Recognized of Change in Contract Liability Balances Related to Collaboration and License Agreements Associated with Partners

During the three months ended March 31, 2020, we recognized the following revenue as a result of the change in the contract liability balances related to our collaboration and license agreements associated with our partners (in thousands):

Revenue recognized in current period from:	Three Months Ended March 31, 2020
Amounts included in deferred revenue at the beginning of the period	$	604

Collaboration and License Agreements [Member]

Summary of Balance of Receivables and Contract Liabilities Related to Net Product Revenue

The following table presents the balance of our receivables and contract liabilities related to our collaboration and license agreements associated with our partners as of March 31, 2020 and December 31, 2019 (in thousands):

	March 31, 2020		December 31, 2019
Receivables included in "Accounts receivable"	$	717	$	3,550
Contract liabilities included in "Deferred revenue"		718		1,322